RT @CUREiHUS: Wauw that is great news! In close collaboration with @MaastrichtUMC #orpandrugs #eculizumab #patientknowsbest https://t.co/nK…
RT @PatientJournal: Here is No.4 in the top 10 downloaded articles in @PatientJournal in 2018. @CUREiHUS https://t.co/Dgm2baxgiO
RT @PatientJournal: Here is No.4 in the top 10 downloaded articles in @PatientJournal in 2018. @CUREiHUS https://t.co/Dgm2baxgiO
Wauw that is great news! In close collaboration with @MaastrichtUMC #orpandrugs #eculizumab #patientknowsbest
Here is No.4 in the top 10 downloaded articles in @PatientJournal in 2018. @CUREiHUS https://t.co/Dgm2baxgiO
Wel done @NierpatientenNL @Longfonds @longfibrose !
RT aHUSAllianceAct RT aHUSUKvoice: Small number of #aHUS patients in the Netherlands involved in testing the development of a patient feedback questionnaire for the experience and satisfaction with treatment.Comparisons made with other drugs and diseases…
RT aHUSAllianceAct RT CUREiHUS: Our article regarding the use of Patient Experiences and Satisfaction with Medications (PESaM) questionnaire in among other #aHUS patients with #orphandrug #eculizumab is available https://t.co/SfHXQwbePj
RT @aHUSUKvoice: Small number of #aHUS patients in the Netherlands involved in testing the development of a patient feedback questionnaire…
Small number of #aHUS patients in the Netherlands involved in testing the development of a patient feedback questionnaire for the experience and satisfaction with treatment.Comparisons made with other drugs and diseases not dialysis.
Our article regarding the use of Patient Experiences and Satisfaction with Medications (PESaM) questionnaire in among other #aHUS patients with #orphandrug #eculizumab is available https://t.co/kpLVsYJ2Ko